Amneal Pharmaceuticals, Inc. AMRX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Amneal Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Amneal Pharmaceuticals, Inc.’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s debt-to-equity?
- Amneal Pharmaceuticals, Inc. (AMRX) reported debt-to-equity of 127.9× in Q4 2023.
- How has Amneal Pharmaceuticals, Inc.'s debt-to-equity changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s debt-to-equity increased by 1290.3% year-over-year, from 9.2× to 127.9×.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s debt-to-equity?
- Over 3 years (2020 to 2023), Amneal Pharmaceuticals, Inc.'s debt-to-equity has grown at a 137.2% compound annual growth rate (CAGR), from 9.6× to 127.9×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.